Schiff base oxovanadium complexes resist the assembly behavior of human islet amyloid polypeptide
作者:Jufei Xu、Gehui Gong、Xiangyi Huang、Weihong Du
DOI:10.1016/j.jinorgbio.2018.05.006
日期:2018.9
peptides, and metal complexes. Vanadium complexes have been applied for the treatment of diabetes since the 19th century. However, the antidiabetes mechanism remains unclear. In this work, we used four Schiff base oxidovanadium(IV) complexes, namely VO(bhbb)·H2O (1, and ligand 1 H2bhbb, 2-(5-bromo-2-hydroxylbenzylideneamino) benzoic acid), VO(nhbb)·H2O (2, and lignad 2 H2nhbb, 2-(5-nitro-2-hydroxylbenzylideneamino)
人胰岛淀粉样多肽(hIAPP)的错误折叠和原纤维化与II型糖尿病(T2DM)的病理过程有关。hIAPP聚集的抑制剂包括芳香族有机分子,短肽和金属络合物。自19世纪以来,钒配合物已被用于治疗糖尿病。但是,抗糖尿病机制仍不清楚。在这项工作中,我们使用了四种席夫碱氧化钒(IV)配合物,即VO(bhbb)·H2O(1和配体1 H2bhbb,2-(5-溴-2-羟基苄基亚氨基)苯甲酸),VO(nhbb)· H2O(2和Lignad 2 H2nhbb,2-(5-硝基-2-羟基苄叉亚氨基)苯甲酸),VO(cpmp)2(3和配体3 Hcpmp,4-氯-2-(苯基亚氨基)甲基)苯酚) ,VO(bpmp)2(4和配体4 Hbpmp,4-溴-2-(苯氨基)甲基)苯酚)抑制hIAPP的原纤维形成并减少肽诱导的细胞毒性。结果表明,四种席夫碱氧化钒配合物有效地阻碍了hIAPP的聚集并将成熟的原纤维分解为单体或低聚物。这